Niagen Bioscience, Inc. Common Stock NAGE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $18.64M+7.2% | $17.38M-14.9% | $20.43M+15.2% | $17.73M+25.7% | $14.11M+65.0% | ||
| $570K-6.9% | $612K-1.9% | $624K-1.1% | $631K-1.9% | $643K-3.0% | ||
| $6.71M+10.6% | $6.07M+19.6% | $5.07M+25.2% | $4.05M+8.1% | $3.75M+2.5% | ||
| —— | —— | —— | $16K-15.8% | $19K0.0% | ||
| —— | —— | —— | —— | -$2.61M-108% | ||
| $13.22M+13.6% | $11.64M+41.1% | $8.25M+185% | $2.9M+321% | -$1.31M+75.4% | ||
| —— | —— | —— | —— | —— | ||
| $507K-72.5% | $1.84M-7.5% | $1.99M+21.2% | $1.64M+11.9% | $1.47M+21.6% | ||
| -$932K+16.9% | -$1.12M-6,128% | -$18K-123% | $78K-40.5% | $131K+191% | ||
| -$58K+1.7% | -$59K0.0% | -$59K+9.2% | -$65K+9.7% | -$72K+10.0% | ||
| —— | —— | —— | -$637K+16.9% | -$767K-4.8% | ||
| $311K+79.8% | $173K+14.6% | $151K0.0% | $151K+0.7% | $150K-0.7% | ||
| -$939K+1.1% | -$949K+0.6% | -$955K-0.8% | -$947K-15.8% | -$818K-33.0% | ||
| $6.21M+721% | $756K— | —— | —— | —— | ||
| $4.43M-67.2% | $13.5M-36.9% | $21.41M+0.9% | $21.21M+6.3% | $19.96M+61.3% | ||
| —— | —— | —— | —— | —— | ||
| $4.99M+1,807% | -$292K-12.3% | -$260K-1.2% | -$257K-91.8% | -$134K+6.3% | ||
| —— | —— | —— | —— | $0— | ||
| $4.24M-41.4% | $7.25M-33.0% | $10.81M-7.6% | $11.7M+36.9% | $8.55M+57.3% | ||
| $9K-25.0% | $12K0.0% | $12K0.0% | $12K+9.1% | $11K0.0% | ||
| $61K-9.0% | $67K+26.4% | $53K— | —— | —— | ||
| $1.6M-77.1% | $7M-34.9% | $10.74M-7.7% | $11.64M+37.1% | $8.49M+58.1% | ||
| $10.93M-45.7% | $20.13M-36.9% | $31.89M-2.1% | $32.59M+16.2% | $28.05M+61.8% | ||
| $311K+79.8% | $173K+14.6% | $151K0.0% | $151K+0.7% | $150K-0.7% | ||
| $570K-6.9% | $612K-1.9% | $624K-1.1% | $631K-1.9% | $643K-3.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | $1.98M+33.3% | $1.49M+50.0% | $991.5K+100% | $495.75K— | ||
| —— | $66K-6.0% | $70.25K-5.7% | $74.5K-5.4% | $78.75K-5.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$24K-106% | ||
| -$939K+1.1% | -$949K+0.6% | -$955K-0.8% | -$947K-15.8% | -$818K-33.0% | ||
| $6.21M+721% | $756K— | —— | —— | —— | ||
| -$932K+16.9% | -$1.12M-6,128% | -$18K-123% | $78K-40.5% | $131K+191% | ||
| —— | —— | —— | —— | —— | ||
| —— | $38K+33.3% | $28.5K+50.0% | $19K+100% | $9.5K— | ||
| —— | —— | —— | —— | —— | ||
| —— | $665K-0.2% | $666.25K-0.2% | $667.5K-0.2% | $668.75K-0.2% | ||
| -$58K+1.7% | -$59K0.0% | -$59K+9.2% | -$65K+9.7% | -$72K+10.0% | ||
| —— | —— | —— | —— | -$2.61M-108% | ||
| —— | $0+100% | -$880.25K+50.0% | -$1.76M+33.3% | -$2.64M+25.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $5K-50.0% | $10K-33.3% | $15K-25.0% | ||
| —— | $292K+12.4% | $259.75K+14.2% | $227.5K+16.5% | $195.25K+19.8% | ||
| —— | —— | —— | —— | —— | ||
| $9K-25.0% | $12K0.0% | $12K0.0% | $12K+9.1% | $11K0.0% | ||
| $61K-9.0% | $67K+26.4% | $53K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $5.47M+33.3% | $4.11M+50.0% | $2.74M+100% | $1.37M— | ||
| —— | —— | —— | —— | —— | ||
| -$939K+1.1% | -$949K+0.6% | -$955K-0.8% | -$947K-15.8% | -$818K-33.0% | ||
| $804K-7.9% | $873K-0.7% | $879K+12.5% | $781K-2.9% | $804K+34.0% | ||
| —— | $1.13M+33.3% | $845.25K+50.0% | $563.5K+100% | $281.75K— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Niagen Bioscience, Inc. Common Stock generate?
- Niagen Bioscience, Inc. Common Stock (NAGE) generated $4.4M in operating cash flow over the trailing twelve months.
- Where does Niagen Bioscience, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
